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Abstract
Solid tumors are associated with an increased risk of suicide, however, there is
limited detailed information on the risk of suicide in patients with hematological
malignancies. Therefore, we conducted a population-based study including
47,220 patients with hematological malignancies (diagnosed 1992–2006) and their
235,868 matched controls to define the incidence and risk factors for suicide and
suicide attempt. Information on suicides, suicide attempts, and preexisting psy-
chiatric disorders was obtained from Swedish registers and individual medical
records. There was a twofold increased (hazard ratio [HR] = 1.9, 95% confidence
interval 1.5–2.3, P < 0.0001) risk of suicide/suicide attempt during the first
3 years after diagnosis in patients with hematological malignancies compared to
matched controls. Of all hematological malignancies, multiple myeloma was asso-
ciated with the highest risk (HR = 3.4; 2.3–5.0, P < 0.0001). Patients with a pre-
existing psychiatric disorder were at a very high risk of suicide and suicide
attempt (HR = 23.3; 16.6–32.6, P < 0.0001), regardless of type of hematological
malignancy. Among patients who committed suicide, 19% were in a palliative
phase and 44% were in remission with no active treatment. In conclusion, the risk
of suicide and suicide attempt is elevated in patients with hematological malig-
nancies. Certain high-risk patients may benefit from early detection and preven-
tive measures.
Introduction
Survival and cure rates have increased in most hematological
malignancies, mainly due to improved disease-specific treat-
ment options and better supportive care [1–6]. Many hema-
tological malignancies are, however, still associated with a
dismal prognosis. In addition, the diseases themselves as well
as their treatment can affect the mental health and quality of
life of these patients [7–10]. An elevated risk of suicides has
been observed in cancer patients compared to the general
population [11, 12]. In patients with solid cancers, risk
factors such as male gender, respiratory, and upper GI-tract
cancers, as well as advanced disease stage, have been associ-
ated with a high suicide risk [11–14]. A few studies where
patients with hematological malignancies have been included
in large subgroups have reported an increased risk of suicide
[11, 13]. However, there is limited detailed information on
the risk and risk factors for suicide and suicide attempt in
patients with different hematological malignancies. There-
fore, we conducted a large population-based study to assess
the incidence and risk factors for suicide and suicide attempt
in patients with a broad range of hematological malignancies.
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Materials and Methods
Central registers, patients, and controls
Sweden, a country of 9.5 million people, provides univer-
sal health care for its entire population. The Swedish Can-
cer Register was established in 1958 [15] and has a high
level of coverage for hematological malignancies [16]. It
is mandatory for every physician and pathologist/cytolo-
gist to report all incident cases of malignant disease to
the Cancer Register. In Sweden, all dates and causes of
death are reported to the Cause of Death Register. Since
1964, the centralized Swedish Inpatient Register holds
information on all somatic and psychiatric hospital dis-
charge diagnoses with a high level of coverage [17].
The Swedish Cancer Register was used to identify all
individuals diagnosed with a hematological malignancy
between 1st January 1992 and 31st December 2006.
Patients under the age of 18 years at diagnosis and
patients with any other malignancy prior to the hemato-
logical malignancy were excluded. For each patient, five
population-based controls, matched by gender, year of
birth, and county of residence, were chosen randomly
from the Swedish Register of Total Population. All con-
trols had to be alive and free of hematologic or nonhema-
tologic malignancy at the time of diagnosis for the
corresponding patient. Controls were censored at time of
death of the corresponding patient.
Information on suicides was obtained from the Cause
of Death Register and hospital admissions due to suicide
attempts were identified through the Inpatient Register.
Suicide and suicide attempt were defined as Intentional
self-harm X60-X84 from ICD10 and Suicide and self-
inflicted injury E950-E959 from ICD9. Events of undeter-
mined intent Y10-Y34 (ICD10) and Injury Undetermined
whether accidental or purposely inflicted E980-E989 (ICD9)
were also included since a substantial portion of these
deaths are considered to be suicides [18, 19]. Information
on admissions due to psychiatric disorders, defined as at
least one admission with any psychiatric diagnosis prior
to the cancer diagnosis, was obtained from the Inpatient
Register.
For patients who committed suicide during the first
3 years after diagnosis, detailed information on patient
characteristics, disease type and stage, as well as treatment
was collected from the patient medical records. The pres-
ence of pain was defined as pain complaints being noted
in the medical record and/or treatment with continuous
analgesics.
The study was approved by the Stockholm Regional Eth-
ics Review Board. Informed consent was waived, because
we had no contact with study patients and the data used
for analyses did not contain any personal identifiers.
Statistical analysis
Patients and controls were followed from the date of
diagnosis or the corresponding time for the controls, until
death, emigration, or end of follow-up. Suicide attempts
were assessed until 31st December 2006 and suicides until
31st December 2005 due to delayed reporting to the
Cause of Death Register. Cox regression was used to ana-
lyze the risk of suicide and suicide attempt and results are
presented at hazard ratios (HRs) with 95% confidence
intervals (CIs). The HRs for suicide and suicide attempt
were analyzed in relation to follow-up time after diagno-
sis, age, and gender. Separate analyses were performed for
the different types of hematological malignancies: non-
Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL),
multiple myeloma (MM), acute leukemia, including acute
myeloid leukemia (AML) and acute lymphoblastic leuke-
mia (ALL), and chronic lympho- and myeloproliferative
disorders, including chronic lymphocytic leukemia (CLL),
chronic myeloid leukemia (CML), and myeloproliferative
neoplasms (MPNs).
The HRs for suicide and suicide attempt were nearly
identical in all separate and combined analysis and are
therefore presented as a combined end point if not other-
wise specified. In addition, incidence of suicide and sui-
cide attempt per thousand person-years of follow-up were
calculated in relation to preexisting psychiatric disorders
in both patients and controls.
Results
A total of 47,220 cases and 235,868 controls were identi-
fied between 1st January 1992 and 31st December 2006.
Of these, 54.6% were men and the median age at diagno-
sis was 70 years (range 18–102 years; Table 1). Median
follow-up was 32 months. The number of patients alive
at 3 years after diagnosis was 28,459 and 18,258 patients
were alive at the end of follow-up.
In total, there were 54 suicides and 158 suicide
attempts among patients (Table 2), of which 36 and 100
occurred during the first 3 years after diagnosis, respec-
tively. The risk of suicide and suicide attempt was twice
as high in patients with hematological malignancies com-
pared to matched controls during the first 3 years after
diagnosis (HR = 1.9, 95% CI 1.5–2.3, P < 0.0001). The
excess risk was modified by time after diagnosis and no
remaining risk-increase was observed when more than
3 years had elapsed (HR = 1.1, 0.9–1.4, P = 0.3). In sep-
arate analysis including only consummated suicides,
identical risks were observed (HR = 1.9, 1.3–2.8
P = 0.0005) during the first 3 years after diagnosis, and
HR 1.2 (0.8–1.8, P = 0.4) after four or more years of
follow-up (Table 2). Due to the very similar HRs for
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suicide, suicide attempt, and the combined end point
suicide and suicide attempt, the following results repre-
sent the combined end point suicide/suicide attempt
occurring during the first 3 years after diagnosis unless
otherwise specified.
MM was associated with the highest risk of suicide and
suicide attempt (HR = 3.4; 2.3–5.0 P < 0.0001) during
the first 3 years after diagnosis. The risk was also signifi-
cantly elevated for patients with NHL (HR = 1.7; 1.2–2.3
P = 0.002). In patients with HL, acute leukemia, and
Table 1. Characteristic of patients with a hematological malignancy and their matched controls.
Patients Controls
N = 47,220 %
Number of
suicides/suicide
attempts N = 235 868 %
Number of
suicides/suicide
attempts
Gender
Women 21,453 45.4 96 107,059 45.4 461
Men 25,767 54.6 116 128,809 54.6 651
Age at diagnosis
18–29 1394 3.0 21 6587 2.8 58
30–39 1602 3.4 13 8008 3.4 64
40–49 3056 6.5 24 15,278 6.5 115
50–59 6628 14.0 38 33,136 14.0 173
60–69 10,384 22.0 39 51,911 22.0 203
70–79 14,786 31.3 49 73,910 31.3 324
80–89 8619 18.3 27 43,073 18.3 168
90 and older 751 1.6 1 3965 1.7 7
Calendar year of diagnosis
1992–1994 8652 18.3 54 43,223 18.3 355
1995–1997 9153 19.4 62 45,688 19.4 314
1998–2000 9440 20.0 42 47,198 20.0 220
2001–2003 9963 21.1 37 49,714 21.1 173
2004–2006 10,012 21.2 17 50,045 21.2 50
Type of hematological malignancy
Non-Hodgkin lymphoma 18,583 39.3 46 NA NA NA
Hodgkin lymphoma 2248 4.8 11 NA NA NA
Multiple myeloma 7778 16.5 37 NA NA NA
Acute leukemia (AML/ALL) 3746 7.9 9 NA NA NA
CLL/CML/MPN 14,865 31.5 33 NA NA NA
Preexisting psychiatric disorder1
Yes 2042 4.3 57 11,027 4.7 262
No 45,178 95.7 155 224,841 95.3 850
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MPN, mye-
loproliferative neoplasm; NA, not applicable.
1Preexisting psychiatric disorder was defined as a hospital admission with a psychiatric diagnosis prior to the diagnosis of the hematological
malignancy.
Table 2. Suicides and suicides attempt in relation to time after diagnosis in patients compared to matched controls.
Number of events
among patients HR 95% CI P-value
Suicides/suicide attempts 212 1.5 1.3–1.8 <0.0001
Suicides 54 1.6 1.2–2.1 0.0018
Suicides/suicide attempts ≤3 years after diagnosis 136 1.9 1.5–2.3 <0.0001
Suicides ≤3 years after diagnosis 36 1.9 1.3–2.8 0.0005
Suicides/suicide attempts >3 years after diagnosis 76 1.1 0.9–1.5 0.29
Suicides >3 years after diagnosis 18 1.2 0.8–1.8 0.38
HR, hazard ratio; CI, confidence interval.
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CLL/CML/MPN there was a tendency toward an
increased risk, however, this was not statistically signifi-
cant (Table 3).
There was a multiplicative interaction regarding the
risk of suicide/suicide attempt in patients with a preexist-
ing psychiatric disorder and a hematological malignancy.
Compared to controls without a preexisting psychiatric
disorder, the HRs of suicide/suicide attempt in patients
with a preexisting psychiatric disorder was 23.3
(16.6–32.6, P < 0.0001), patients without preexisting psy-
chiatric disorder HR = 1.8 (1.4–2.3, P < 0.0001) and con-
trols with a preexisting psychiatric disorder HR = 10.8
(8.8–13.2, P < 0.0001) during the first 3 years of follow-
up (Table 4). A similar pattern was observed when the
incidence of suicides/suicide attempts per 1000 person-
years was calculated in patients and controls with and
without a preexisting psychiatric disorder (Fig. 1).
The excess risk of suicide/suicide attempt associated
with hematological malignancy was not significantly mod-
ified by age at diagnosis. The HR for patients ≤69 years
at diagnosis was 1.9 (1.5–2.5) and for patients ≥70 years
at diagnosis was 1.8 (1.3–2.4; Table 3). The absolute
number of suicides/suicide attempts was higher in males,
however, the relative risks were similar in the two gen-
ders. The HRs were 1.7 (1.3–2.2) and 2.1 (1.5–2.7;
P = 0.38 for difference), in males and females, respec-
tively (Table 3). There was a trend toward a lower risk in
patients diagnosed between 1999 and 2006 (HR = 1.6;
1.2–2.1) compared to patients diagnosed between 1992
and 1998 (HR = 2.2; 1.7–2.9) although this difference was
not statistically significant (P = 0.07; Table 3).
Thirty-six patients committed suicide during the first
3 years after diagnosis, of which 23 had NHL, nine had
MM, two had AML, and two had polycythemia vera.
Twelve patients (33%) were on active treatment which
included corticosteroids in ten patients (28%). Sixteen
patients (44%) were in remission with no ongoing treat-
ment and seven patients (19%) were in a palliative phase.
Pain was noted in the medical record of 14 patients
(39%). Seventeen patients (47%) had a preexisting psy-
chiatric disorder and nine patients (25%) had attempted
to commit suicide prior to their cancer diagnosis
(Table 5). The most commonly used methods of suicide
were hanging and intoxication. Suicides including fire-
arms were only seen in men.
Discussion
In this large population-based study we found the risk of
suicide and suicide attempt to be twice as high in patients
with hematological malignancies compared to matched
controls. The risk was elevated during the first 3 years
after diagnosis while no excess risk was observed when
Table 3. Risk of suicide/suicide attempt in relation to calendar period,
gender, age, type of hematological malignancy, and history of psychi-
atric disorder during the first 3 years after diagnosis.
Year 0–3 of follow-up after diagnosis
Number of
events among
patients HR 95% CI P-value
Gender
Male 72 1.7 1.3–2.2
Female 64 2.1 1.5–2.7 0.38
Age at diagnosis
≤69 63 1.9 1.5–2.5
≥70 73 1.8 1.3–2.4 0.76
Calendar period of diagnosis
1992–1998 80 2.2 1.7–2.9
1999–2006 56 1.6 1.2–2.1 0.065
Type of hematological malignancy
Non-Hodgkin lymphoma 46 1.7 1.2–2.3
Hodgkin lymphoma 11 1.8 0.9–3.6
Multiple myeloma 37 3.4 2.3–5.0
Acute leukemia
(AML/ALL)
9 1.9 0.9–4.1
CLL/CML/MPN 33 1.5 0.99–2.1 0.0011
HR, hazard ratio; CI, confidence interval; AML, acute myeloid leuke-
mia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leu-
kemia; CML, chronic myeloid leukemia; MPN, myeloproliferative
neoplasm.
1Test of homogeneity. This significance is mainly attributed to a
higher risk for multiple myeloma.
Table 4. Risk of suicide/suicide attempt in relation to history of psychiatric disorder during the first 3 years after diagnosis of the hematological
malignancy.
Year 0–3 of follow-up after diagnosis
Number of events
among patients HR 95% CI P-value
Patients without a preexisting psychiatric disorder (n = 45,178) 92 1.8 1.4–2.3 <0.0001
Patients with a preexisting psychiatric disorder (n = 2042) 44 23.3 16.7–32.6 <0.0001
Controls without a preexisting psychiatric disorder (n = 224,841) 325 1.0 NA Reference
Controls with a preexisting psychiatric disorder (n = 11,027) 147 10.8 8.3–13.2 <0.0001
HR, hazard ratio; CI, confidence interval; NA, not applicable.
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more than 3 years had elapsed. The highest risks were
observed in patients with MM and in patients with a
preexisting psychiatric disorder irrespective of type of
hematological malignancy. Even though the absolute
number of suicides/suicide attempts was limited, there are
patients at high risk of committing suicide who may ben-
efit from early detection and preventive measures.
Patients with a hematological malignancy were at a
higher risk of committing suicide/suicide attempt shortly
after diagnosis. In a recent Swedish study, the risk of sui-
cide and cardiovascular death was significantly elevated
during the first year, even the first weeks, after receiving a
diagnosis of cancer emphasizing that a cancer diagnosis is
a traumatic experience associated with both emotional
and physical stress [20]. Similar temporal patterns have
been observed in large studies on cancer patients where
patients with hematological malignancies have been
included [11–13]. After more than 3 years following diag-
nosis, patients who are still alive may either be cured or
may have adapted emotionally to having a malignant dis-
ease. The awareness of suicidal ideation in patients should
be higher among health care personnel shortly after the
cancer diagnosis.
MM was the hematological malignancy associated with
the highest risk of suicide/suicide attempt. MM is in the
majority of cases an incurable disease and often associated
with debilitating bone lesions and pain [8, 21]. Also, the
treatment can have a negative impact on quality of life;
high doses of corticosteroids, included in most MM treat-
ment regimen, can induce depression and psychosis and
thus enhance the risk of suicide/suicide attempt [22, 23].
There are recent studies indicating that early treatment,
before organ damage is evident, may improve survival in
MM patients [24]. Optimizing MM management, possibly
by more effective novel therapies earlier in the disease
course, and better psychological care is of great impor-
tance for improving survival and quality of life in MM
patients.
An elevated risk of suicide/suicide attempt was also
observed in patients with NHL while HL, acute leukemias
and CLL/CML/MPN were all associated with a nonsignifi-
cant increase in risk of suicide/suicide attempt. There was
also a trend toward a lower risk of suicide/suicide attempt
toward the second calendar period. In previous studies,
patients with aggressive diseases and poor prognosis such
as acute leukemias have been observed to have an ele-
vated risk of suicide/suicide attempt [12, 25]. New
treatment options have emerged for many of the hemato-
logical malignancies during the current study period [4,
5, 26]. The majority of the recently introduced treatments
have a favorable effect on both survival and quality of life
but their potential impact on risk of suicide and suicidal
ideation needs to be elucidated.
Patients with a preexisting psychiatric disorder had a
substantially elevated risk of suicide/suicide attempt
compared to controls regardless of type of hematological
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Figure 1. Suicide and suicide attempt among patients and controls
with and without a preexisting psychiatric disorder per year, starting
at diagnosis shown as incidence/1000 person-years.
Table 5. Demography, disease characteristics, and suicide methods in
patients who committed suicide during the first 3 years after diagno-
sis
Patients Number
Median age at diagnosis 68.5 (years)
Median age at suicide 69 (years)
Men 23
Women 13
Type of hematological malignancy
Multiple myeloma 9
Non-Hodgkin lymphoma 23
Acute myeloid leukemia 2
Polycythemia vera 2
Patient and disease characteristics Yes No
Preexisting psychiatric disorder 17 18
Previous suicide attempt 9 26
Active treatment 12 23
Including corticosteroids 10 25
In remission with no ongoing treatment 16 19
Palliation 7 28
Substantial pain 14 21
Unknown n = 1
Method of suicide Men Women
Hanging 6 4
Intoxication with sedatives/analgesics 5 3
Fall/jump 4 2
Drowning 1 4
Firearm 4 –
Burn/fire 3 –
Total 23 13
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malignancy. Psychiatric disorders including depression
should be recognized as a major risk factor for suicide/
suicide attempt in patients with hematological malignan-
cies. In addition, depression is more common in can-
cer patients and has been shown to correlate with more
rapid cancer progression [27–31]. Interestingly, there are
hypotheses of an immunological interaction between can-
cer and depression. Dysregulation of the hypothalamo–
pituitary–adrenal axis and production of proinflammatory
cytokines have been shown to correlate both with depres-
sion and cancer [32–34]. Especially interleukin-6 has been
correlated to MM progression as well as to cancer-related
depression and fatigue [35, 36]. This potential immuno-
logical relationship needs to be further clarified and if the
association is shown to be causative, it may have great
implications for the treatment of various cancers and can-
cer-related depression.
The first step of suicide prevention is to identify patients
at an increased risk, which in our study were patients who
were recently diagnosed, patients with MM, and patients
with a preexisting psychiatric disorder. In the detailed
analysis of the 36 patients who committed suicide, preexist-
ing psychiatric disorders and previous suicide attempts
were common. Depression was the most common psychi-
atric disorder, followed by alcohol abuse. Additional risk
factors observed in previous studies are male gender, poor
social support, emotional distress, pain, and advanced dis-
ease stage [27, 33, 37]. The 14 of the 36 patients who were
in remission with no preexisting psychiatric disorder would
have been harder to identify at an earlier stage. Therefore, a
high awareness of suicidal ideation in patients shortly after
diagnosis but also during follow-up is important. Early
identification of high-risk patients is valuable since effective
treatment in multidisciplinary teams, including psychologi-
cal intervention and antidepressive treatment, can lead to a
better quality of life and may reduce the risk of suicide and
suicide attempt [29, 31, 37, 38].
Strengths of this study include the population-based
design and a large number of patients during a period of
16 years. In addition, the study includes information
from both high-quality Swedish registers as well as
detailed information from individual medical records.
One limitation is the possibility of underreporting of sui-
cides in cancer patients. Suicides in cancer patients may
go unnoticed and in addition, doctors may be reluctant
to report suicides in terminally ill patients. The number
of suicide attempts and the prevalence of preexisting psy-
chiatric disorders may be underestimated since the Inpa-
tient Register does not include patients treated in the
outpatient setting. Thus, less severe suicide attempts and
milder psychiatric disorders were not included and the
study was instead focused on patients/controls with sig-
nificant suicide attempts and more pronounced psychiat-
ric disorders. Moreover, psychiatric complaints emerging
after the cancer diagnosis are not analyzed in this study.
In summary, in this large population-based study we
found patients with hematological malignancies, especially
MM, to have a higher risk of suicide and suicide attempt
compared to matched controls during the first 3 years
following diagnosis. The risk elevation was strongly asso-
ciated with a preexisting psychiatric disorder. Future
studies are required to elucidate underlying neuropsychi-
atric and immunological causes, which may be shared in
depression and cancer. Even though suicides/suicide
attempts were rare events, awareness of risk factors such
as short time since diagnosis, MM diagnosis, male gender,
advanced disease stage, and a preexisting psychiatric dis-
order is important. Our results emphasize, in addition to
optimal treatment of the malignant disease, the need for
psychological assessment and early detection of cancer
patients at high risk of committing suicide in order to
enable effective prevention of suicides/suicide attempts.
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